[EZH2 is therapeutic target for personalized treatment in multiple myeloma]. / Rôle de EZH2 comme biomarqueur dans le traitement personnalisé du myélome multiple.
Bull Cancer
; 105(9): 804-819, 2018 Sep.
Article
em Fr
| MEDLINE
| ID: mdl-30041976
ABSTRACT
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that functions as the catalytic subunit of the polycomb repressive complex 2 (PRC2). PRC2 represses gene transcription through tri-methylation of lysine 27 of histone 3 (H3K27me3) by its catalytic subunit EZH2. EZH2 is also involved in normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. The oncogenic addiction of tumor cells to EZH2 represents a therapeutic target in several hematological malignancies and solid cancers. Specific small molecules have been recently developed to target cancer cells with EZH2 overexpression or activating mutation. Their therapeutic potential is currently under evaluation. In particular, EZH2 is overexpressed in multiple myeloma (MM), a neoplasia characterized by the accumulation of clonal plasma cells within the bone marrow, with biological functions in the pathophysiology. This review summarizes the roles of EZH2 in B cell differentiation and pathologic hematological processes with a particular focus in multiple myeloma. We also discuss recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos B
/
Diferenciação Celular
/
Terapia de Alvo Molecular
/
Proteína Potenciadora do Homólogo 2 de Zeste
/
Mieloma Múltiplo
/
Proteínas de Neoplasias
Limite:
Humans
Idioma:
Fr
Ano de publicação:
2018
Tipo de documento:
Article